A Phase 1, Open-label, 2-period, Fixed Sequence Study Of The Effect Of A Proton Pump Inhibitor On The Relative Bioavailability Of The Proposed Commercial Tablet Formulation Of Palbociclib In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Rabeprazole
- Indications Brain metastases; Breast cancer; Cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 08 Oct 2017 Status changed from active, no longer recruiting to completed.
- 08 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.